111 Inc. (1药网) IPO Review - Key Operating Metrics of B2C Segment Has Been Declining
111 Inc (YI US) is looking to raise up to about US$150m in its upcoming IPO. Proceeds from IPO will be mainly used for research and development and...
344 Views
Last Week in GER Research: Meituan-Dianping, Nio, Gangfeng Lithium, Pinduoduo and 111 Inc
Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a more palatable...
336 Views
111 Inc IPO Valuation: Pricing Does Not Adequately Reflect the Risks
111 Inc (YI US) announced its IPO price range of $14-16 per ADS. At the mid-point of the IPO price range, 111 will raise net proceeds of...
554 Views
Last Week in GER Research: Haidilao, Xiaomi, Ping An, 111, Qutoutiao, Nio and Tesla
Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a differentiated...
370 Views
111 Inc IPO Preview: A New Business Papers over the Cracks
111 Inc (1647603D CH) runs an online retail drugstore (1 Drugstore) and healthcare platform in China. 1 Drugstore is the largest direct sales...
698 Views